Lantheus Stock Price, News & Analysis (NASDAQ:LNTH) $73.71 +5.18 (+7.56%) (As of 12/8/2023 ET) Add Compare Share Share Today's Range$68.24▼$74.3850-Day Range$61.58▼$76.3452-Week Range$47.46▼$100.85Volume949,969 shsAverage Volume1.01 million shsMarket Capitalization$5.05 billionP/E Ratio51.55Dividend YieldN/APrice Target$110.71 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainabilityStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainability Lantheus MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside50.2% Upside$110.71 Price TargetShort InterestBearish7.09% of Float Sold ShortDividend StrengthN/ASustainability-1.67Upright™ Environmental ScoreNews Sentiment0.75Based on 9 Articles This WeekInsider TradingSelling Shares$1.06 M Sold Last QuarterProj. Earnings Growth3.20%From $5.31 to $5.48 Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.91 out of 5 starsMedical Sector36th out of 954 stocksDrug Manufacturers - Specialty & Generic Industry2nd out of 19 stocks 4.5 Analyst's Opinion Consensus RatingLantheus has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 7 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $110.71, Lantheus has a forecasted upside of 50.2% from its current price of $73.71.Amount of Analyst CoverageLantheus has been the subject of 7 research reports in the past 90 days, demonstrating strong analyst interest in this stock. Previous Next 2.0 Short Interest Percentage of Shares Shorted7.09% of the float of Lantheus has been sold short.Short Interest Ratio / Days to CoverLantheus has a short interest ratio ("days to cover") of 5.1.Change versus previous monthShort interest in Lantheus has recently decreased by 1.86%, indicating that investor sentiment is improving. Previous Next 0.0 Dividend Strength Dividend YieldLantheus does not currently pay a dividend.Dividend GrowthLantheus does not have a long track record of dividend growth. Previous Next 4.2 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreLantheus has received a 61.07% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is mostly driven by its "Clinical research services for cancer", "Diagnostic radiopharmaceuticals", and "Therapeutic radiopharmaceuticals" products. See details.Environmental SustainabilityThe Environmental Impact score for Lantheus is -1.67. Previous Next 3.2 News and Social Media Coverage News SentimentLantheus has a news sentiment score of 0.75. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.52 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 9 news articles for Lantheus this week, compared to 5 articles on an average week.Search InterestOnly 12 people have searched for LNTH on MarketBeat in the last 30 days. This is a decrease of -29% compared to the previous 30 days.MarketBeat Follows8 people have added Lantheus to their MarketBeat watchlist in the last 30 days. This is an increase of 33% compared to the previous 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Lantheus insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $1,063,299.00 in company stock.Percentage Held by InsidersOnly 1.50% of the stock of Lantheus is held by insiders.Percentage Held by Institutions99.06% of the stock of Lantheus is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 1.9 Earnings and Valuation Earnings GrowthEarnings for Lantheus are expected to grow by 3.20% in the coming year, from $5.31 to $5.48 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Lantheus is 51.55, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 120.43.Price to Earnings Ratio vs. SectorThe P/E ratio of Lantheus is 51.55, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 130.09.Price to Book Value per Share RatioLantheus has a P/B Ratio of 11.34. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Lantheus Stock (NASDAQ:LNTH)Lantheus Holdings, Inc. develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine; Xenon-133 to assess pulmonary function; Neurolite to identify the area within the brain where blood flow has been blocked or reduced due to stroke; and Cardiolite, an injectable Tc-99m-labeled imaging agent. The company also offers AZEDRA, a radiotherapeutic therapy; Automated Bone Scan Index that calculates the disease burden of prostate cancer by detecting and classifying bone scan tracer uptakes as metastatic or benign lesions using an artificial neural network; RELISTOR for opioid-induced constipation; and PYLARIFY for visualization of lymph nodes, bone, and soft tissue metastases to determine the presence or absence of recurrent and/or metastatic prostate cancer. It also develops flurpiridaz to assess blood flow to the heart; 1095, a PSMA-targeted iodine-131 labeled small molecule; PNT2002 for pre-chemotherapy patients; PNT2003, an SSTR therapy that treats patients with SSTR-positive neuroendocrine tumors; and PYLARIFY AI, an AI-based medical device software to perform standardized quantitative assessment of PSMA PET/CT images in prostate cancer. The company serves hospitals, independent diagnostic testing facilities, government facilities, integrated delivery networks, radiopharmacies, clinics, distirbutors, and group practices. It has strategic partnerships with NanoMab Technology Limited; Bausch Health Companies, Inc.; GE Healthcare Limited; and FUJIFILM. The company was founded in 1956 and is based in Bedford, Massachusetts.Read More LNTH Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart LNTH Stock News HeadlinesDecember 5, 2023 | markets.businessinsider.comStrong Market Outlook for Lantheus’s Pylarify and Therapeutic Candidate PNT2002 Reinforces Buy RatingDecember 5, 2023 | americanbankingnews.comTD Cowen Initiates Coverage on Lantheus (NASDAQ:LNTH)December 8, 2023 | Wealthpress (Ad)Trading Experts Call It “The Perfect Tesla Trade”Thanks to a new discovery linked to shares of Tesla, regular folks can now target gains of 100% or more in six days or less. New research shows it’s happened 23 different times this year. The next trade is scheduled for this Thursday.December 4, 2023 | markets.businessinsider.comBuy Rating Affirmed for Lantheus: Strong Market Position and Growth Prospects in Precision DiagnosticsDecember 1, 2023 | americanbankingnews.comLantheus (NASDAQ:LNTH) Coverage Initiated by Analysts at Brookline Capital ManagementNovember 30, 2023 | benzinga.comLantheus Holdings Stock (NASDAQ:LNTH) Dividends: History, Yield and DatesNovember 30, 2023 | msn.comBrookline Capital Initiates Coverage of Lantheus Holdings (LNTH) with Buy RecommendationNovember 30, 2023 | markets.businessinsider.comThe Latest Analyst Ratings for Lantheus HoldingsDecember 8, 2023 | DTI Trader (Ad)All the trading advice you’ve ever received boils down to thisAll the trading advice you’ve ever received boils down to one goal and one goal only: finding a reliable edge in the markets. If you can do that, grab hold of it and never let go. Because once you have that edge, and you can count on it, you never need to do anything else.November 22, 2023 | finance.yahoo.comInvestors Met With Slowing Returns on Capital At Lantheus Holdings (NASDAQ:LNTH)November 22, 2023 | morningstar.comLantheus Holdings Inc LNTHNovember 12, 2023 | seekingalpha.comLantheus Holdings: Huge Catalysts Ahead And Cheap ValuationNovember 6, 2023 | markets.businessinsider.comUndervalued Lantheus: High-Growth Prospects and Potential Expansion Opportunities Support Buy RatingNovember 6, 2023 | markets.businessinsider.comStrong Q3 2023 Performance and Future Potential Drive Analyst’s Buy Rating for LantheusNovember 5, 2023 | finance.yahoo.comAn Intrinsic Calculation For Lantheus Holdings, Inc. (NASDAQ:LNTH) Suggests It's 22% UndervaluedNovember 4, 2023 | finance.yahoo.comLantheus Holdings, Inc. (NASDAQ:LNTH) Q3 2023 Earnings Call TranscriptNovember 4, 2023 | benzinga.comLantheus Holdings Stock (NASDAQ:LNTH), Analyst Ratings, Price Targets, PredictionsNovember 3, 2023 | markets.businessinsider.comStrong Financial Performance and Growth Potential Drive Buy Rating for Lantheus: An Analysis of Undervalued Stock in the MedTech SectorNovember 3, 2023 | markets.businessinsider.comLantheus’ Strong Financial Performance and Promising Radiopharmaceuticals Drive Analyst’s Buy Rating and $114 Price TargetNovember 3, 2023 | markets.businessinsider.comPositive Growth Prospects and Resilient Financial Performance Reinforce Buy Rating for Lantheus Holdings, Inc.November 2, 2023 | seekingalpha.comLantheus Holdings, Inc. 2023 Q3 - Results - Earnings Call PresentationNovember 2, 2023 | finance.yahoo.comCompared to Estimates, Lantheus Holdings (LNTH) Q3 Earnings: A Look at Key MetricsNovember 2, 2023 | markets.businessinsider.comLantheus Reports Third Quarter 2023 Financial ResultsNovember 2, 2023 | finance.yahoo.comLantheus Holdings Inc (LNTH) Reports 33.7% Increase in Q3 2023 Revenue and Doubled Net IncomeNovember 1, 2023 | finance.yahoo.comLantheus (LNTH) to Report Q3 Earnings: What's in the Cards?October 26, 2023 | finance.yahoo.comLantheus Holdings (LNTH) Stock Moves -1.02%: What You Should KnowOctober 19, 2023 | msn.comLantheus Holdings (LNTH) Falls More Steeply Than Broader Market: What Investors Need to KnowSee More Headlines Receive LNTH Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Lantheus and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings11/02/2023Today12/08/2023Fiscal Year End12/31/2023Next Earnings (Estimated)2/22/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Drug Manufacturers - Specialty & Generic Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:LNTH CUSIPN/A CIK1521036 Webwww.lantheus.com Phone(978) 671-8001Fax978-671-8860Employees698Year FoundedN/APrice Target and Rating Average Stock Price Target$110.71 High Stock Price Target$127.00 Low Stock Price Target$100.00 Potential Upside/Downside+50.2%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage7 Analysts Profitability EPS (Most Recent Fiscal Year)$1.43 Trailing P/E Ratio51.55 Forward P/E Ratio13.88 P/E GrowthN/ANet Income$28.07 million Net Margins8.63% Pretax Margin7.99% Return on Equity70.13% Return on Assets27.19% Debt Debt-to-Equity Ratio0.80 Current Ratio5.37 Quick Ratio5.05 Sales & Book Value Annual Sales$1.21 billion Price / Sales4.19 Cash Flow$4.73 per share Price / Cash Flow15.60 Book Value$6.50 per share Price / Book11.34Miscellaneous Outstanding Shares68,489,000Free Float67,462,000Market Cap$5.05 billion OptionableOptionable Beta0.66 20 Stocks to Sell NowMarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.Get This Free Report Key ExecutivesMs. Mary Anne Heino (Age 63)CEO & Director Comp: $2.23MMr. Paul M. Blanchfield (Age 42)President Comp: $962.41kMr. Robert J. Marshall Jr. (Age 56)CFA, CFO & Treasurer Comp: $1.06MMr. Daniel M. Niedzwiecki (Age 46)Chief Administrative Officer, General Counsel & Corporate Secretary Comp: $871.93kMr. Etienne Montagut (Age 48)Chief Business Officer Comp: $789.15kMs. Andrea Sabens (Age 44)Chief Accounting Officer Ms. Dorothy BarrSenior Vice President of Manufacturing & Technical OperationsMr. Mark Richard KinarneySenior Director of Investor RelationsMs. Linda S. Lennox (Age 57)VP of Corporate Communications & Chief of Staff Ms. Carol Walker (Age 60)Senior Vice President of Quality More ExecutivesKey CompetitorsElanco Animal HealthNYSE:ELANRiot PlatformsNASDAQ:RIOTIntellia TherapeuticsNASDAQ:NTLAMyriad GeneticsNASDAQ:MYGNCelldex TherapeuticsNASDAQ:CLDXView All CompetitorsInsiders & InstitutionsCitigroup Inc.Sold 23,523 shares on 12/6/2023Ownership: 0.039%Tucker Asset Management LLCBought 282 shares on 12/4/2023Ownership: 0.001%Wellington Management Group LLPBought 5,172 shares on 12/1/2023Ownership: 0.605%American Century Companies Inc.Bought 384,093 shares on 11/30/2023Ownership: 1.899%Decheng Capital Management III Cayman LLCBought 142,196 shares on 11/29/2023Ownership: 0.208%View All Insider TransactionsView All Institutional Transactions LNTH Stock Analysis - Frequently Asked Questions Should I buy or sell Lantheus stock right now? 7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Lantheus in the last twelve months. There are currently 7 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" LNTH shares. View LNTH analyst ratings or view top-rated stocks. What is Lantheus' stock price target for 2024? 7 equities research analysts have issued 12 month price objectives for Lantheus' stock. Their LNTH share price targets range from $100.00 to $127.00. On average, they predict the company's share price to reach $110.71 in the next twelve months. This suggests a possible upside of 50.2% from the stock's current price. View analysts price targets for LNTH or view top-rated stocks among Wall Street analysts. How have LNTH shares performed in 2023? Lantheus' stock was trading at $50.96 at the start of the year. Since then, LNTH stock has increased by 44.6% and is now trading at $73.71. View the best growth stocks for 2023 here. When is Lantheus' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, February 22nd 2024. View our LNTH earnings forecast. How were Lantheus' earnings last quarter? Lantheus Holdings, Inc. (NASDAQ:LNTH) released its earnings results on Thursday, November, 2nd. The medical equipment provider reported $1.29 EPS for the quarter, topping the consensus estimate of $1.19 by $0.10. The medical equipment provider earned $319.95 million during the quarter, compared to analysts' expectations of $315.01 million. Lantheus had a trailing twelve-month return on equity of 70.13% and a net margin of 8.63%. What ETFs hold Lantheus' stock? ETFs with the largest weight of Lantheus (NASDAQ:LNTH) stock in their portfolio include Harbor Health Care ETF (MEDI), Invesco S&P MidCap Momentum ETF (XMMO), SPDR S&P Health Care Equipment ETF (XHE), Harbor Small Cap Explorer ETF (QWST), American Century Mid Cap Growth Impact (MID), Invesco S&P MidCap 400 Pure Growth ETF (RFG), First Trust Active Factor Small Cap ETF (AFSM) and SoFi Next 500 ETF (SFYX). What guidance has Lantheus issued on next quarter's earnings? Lantheus issued an update on its FY23 earnings guidance on Thursday, November, 2nd. The company provided EPS guidance of $5.60-$5.70 for the period, compared to the consensus EPS estimate of $5.68. The company issued revenue guidance of $1.245-$1.270 billion, compared to the consensus revenue estimate of $1.26 billion. What is Mary Anne Heino's approval rating as Lantheus' CEO? 4 employees have rated Lantheus Chief Executive Officer Mary Anne Heino on Glassdoor.com. Mary Anne Heino has an approval rating of 51% among the company's employees. This puts Mary Anne Heino in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies. What other stocks do shareholders of Lantheus own? Based on aggregate information from My MarketBeat watchlists, some companies that other Lantheus investors own include (MBBYF) (MBBYF), Energy Transfer (ET), Paratek Pharmaceuticals (PRTK), Catalyst Pharmaceuticals (CPRX), Amicus Therapeutics (FOLD), Anavex Life Sciences (AVXL), Exelixis (EXEL), Gerdau (GGB), Pieris Pharmaceuticals (PIRS) and Abeona Therapeutics (ABEO). When did Lantheus IPO? (LNTH) raised $75 million in an initial public offering (IPO) on Thursday, June 25th 2015. The company issued 7,900,000 shares at $8.50-$10.50 per share. Citigroup, Jefferies, RBC Capital Markets and Wells Fargo Securities served as the underwriters for the IPO and Baird was co-manager. Who are Lantheus' major shareholders? Lantheus' stock is owned by a number of retail and institutional investors. Top institutional shareholders include FMR LLC (3.13%), American Century Companies Inc. (1.90%), Westfield Capital Management Co. LP (1.89%), Invesco Ltd. (1.54%), Northern Trust Corp (1.44%) and Reinhart Partners LLC. (1.32%). Insiders that own company stock include Andrea Sabens, Brian A Markison, Carol Walker, Daniel Niedzwiecki, Etienne Montagut, Gerard Ber, Heinz Christoph Maeusli, John J Bolla, Mary Anne Heino, Michael P Duffy, Michael P Duffy, Minnie Baylor-Henry, Paul Blanchfield, Robert J Jr Marshall and Sam R Leno. View institutional ownership trends. How do I buy shares of Lantheus? Shares of LNTH stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. This page (NASDAQ:LNTH) was last updated on 12/8/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Lantheus Holdings, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.